1981
Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy.
Whang-Peng J, Lees D, Schuette W, Smith R, Bull J, DeVita V. Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy. Journal Of The National Cancer Institute 1981, 65: 1103-4. PMID: 7296555.Peer-Reviewed Original ResearchHigh-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaDialysisFemaleHumansInjections, IntraperitonealMelanomaMethotrexateOvarian NeoplasmsConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvivalHexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologic
1976
Perspectives on research in gynecologic oncology. Treatment protocols
Devita V, Wasserman T, Young R, Carter S. Perspectives on research in gynecologic oncology. Treatment protocols. Cancer 1976, 38: 509-525. PMID: 776390, DOI: 10.1002/1097-0142(197607)38:1<509::aid-cncr2820380175>3.0.co;2-a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAlkylating AgentsAntineoplastic AgentsCarcinoma, Squamous CellClinical Trials as TopicDrug EvaluationDrug Therapy, CombinationFemaleGenital Neoplasms, FemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsProgestinsUterine Cervical NeoplasmsUterine NeoplasmsConceptsClinical trialsOvarian cancerAdvanced uterine cancerPostoperative adjuvant chemotherapyStage II diseaseMetastatic cervical cancerEffective adjuvant treatmentEffect of radiotherapyUse of adriamycinUse of hydroxyureaCombination of drugsL-phenylalanine mustardPathways of spreadMore effective drugsAdjuvant chemotherapyInoperable diseaseResectable tumorsAdjuvant treatmentAdvanced diseasePostoperative radiotherapySystemic chemotherapyGynecologic malignanciesSystemic treatmentTreatment failureUterine cervix
1974
Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide
Young R, Canellos G, Chabner B, Schein P, Hubbard S, DeVita V. Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974, 2: 489-497. PMID: 4376998, DOI: 10.1016/0090-8258(74)90059-6.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaComplete remissionMedian durationOvarian carcinomaLong-term disease-free survivalTerm disease free survivalHigh-dose cyclophosphamideDisease-free survivalProspective Randomized ComparisonDose cyclophosphamideIntravenous cyclophosphamideIntensive regimenMelphalan therapyFree survivalInitial remissionMedian survivalUnacceptable toxicityUntreated patientsAgent therapyRandomized comparisonPresent studyHigh dosePhenylalanine mustardRemissionChemotherapyThe design of clinical trials in the therapy of ovarian carcinoma
Young R, DeVita V. The design of clinical trials in the therapy of ovarian carcinoma. American Journal Of Obstetrics And Gynecology 1974, 120: 1012-1024. PMID: 4432892, DOI: 10.1016/0002-9378(74)90143-4.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCystadenocarcinomaCystadenomaEndometriosisFemaleHumansOvarian NeoplasmsPrognosisResearch DesignConceptsOvarian carcinomaClinical trialsProspective randomized clinical trialsSurvival of patientsCombined modality approachRandomized clinical trialsPrognostic factorsStandardized stagingModality approachTherapySuch trialsCarcinomaMajor causeTrialsPatientsBase lineSurvivalChemotherapyRadiotherapyStagingWomenIndomethacin-Responsive Hypercalcemia in a Patient with Renal-Cell Adenocarcinoma
Brereton H, Halushka P, Alexander R, Mason D, Keiser H, DeVita V. Indomethacin-Responsive Hypercalcemia in a Patient with Renal-Cell Adenocarcinoma. New England Journal Of Medicine 1974, 291: 83-85. PMID: 4835887, DOI: 10.1056/nejm197407112910207.Peer-Reviewed Original Research
1972
Treatment of Ovarian Carcinoma: Possibilities for Progress
Bagley C, Young R, Canellos G, DeVita V. Treatment of Ovarian Carcinoma: Possibilities for Progress. New England Journal Of Medicine 1972, 287: 856-862. PMID: 4561148, DOI: 10.1056/nejm197210262871705.Peer-Reviewed Original Research